Mometasone furoate

From Self-sufficiency
Revision as of 10:07, 20 September 2010 by Jontas (Talk | contribs) (1 revision)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Mometasone furoate
File:Mometasone furoate.png
Systematic (IUPAC) name
(11β,16α)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
topical, nasal
Legal status
Legal status
  • Rx Only (US)
Pharmacokinetic data
Bioavailability Nasal spray is virtually undetectable in plasma; but systemic availability is comparable to fluticasone.[1]
Protein binding 98% to 99%
Metabolism hepatic
Biological half-life 5.8 hours
Identifiers
CAS Number 105102-22-5 83919-23-7 as Furoate
ATC code D07AC13 (WHO) D07XC03, R01AD09, R03BA07
PubChem CID 123620
DrugBank APRD00289
Synonyms (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
Chemical data
Formula C22H28Cl2O4 for Mometasone
C27H30O6Cl2 as Furoate
Molar mass 427.361 g/mol (Mometasone)
521.4 g/mol (Furoate)
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Mometasone furoate (also referred to as mometasone) is a glucocorticoid steroid used topically to reduce inflammation of the skin or in the airways.

Uses, administration, and pharmacodynamics

Mometasone furoate is used in the treatment of inflammatory skin disorders (such as eczema and psoriasis), allergic rhinitis (such as hay fever), asthma[2][3] for patients unresponsive to less potent corticosteroids, and penile phimosis [4]. In terms of steroid strength, it is more potent than hydrocortisone, and less potent than dexamethasone.[citation needed]

It reduces inflammation by causing several effects:[5][6]

  • reversing the activation of inflammatory genes
  • activating the secretion of anti-inflammatory proteins
  • stabilising cell membranes
  • decreasing the influx of inflammatory cells

Availability

Schering-Plough markets the medication under the following brand names; Elocon (Elocom, Elomet) as a cream or ointment for skin conditions, Nasonex as a nasal spray for upper respiratory conditions such as nasal sinus inflammation, Asmanex Twisthaler as a dry powder inhaler (DPI) for lower respiratory conditions. Essex pharma markets the medication under the brand name Ecural.

It is also available as a veterinary drug in an otic (ears) form for treatment of otitis externa under the brand name Mometamax.[7]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

hu:Mometazon-furoát

nl:Mometasonfuroaat pl:Mometazon pt:Mometasona

ru:Мометазона фуроат
  1. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  4. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  5. Publishers, Jones and Bartlett (2009-07-15). "Nurse's Drug Handbook 2010". p. 677. ISBN 9780763779009. 
  6. Mani S. Kavuru (2007). "ch. 9 Anti-inflammatory agents". Diagnosis and Management of Asthma. ISBN 9781932610383. 
  7. "Mometamax". Intervet USA. Retrieved 19 June 2010.